patent/CN-101652142-B

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101652142-B

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aecc3010d5116cda846ee1bd66f4fc93
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-582
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J7-00
filingDate	2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate	2013-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06862fe06e2effda2dae367403bde21f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13a3557d68e30a7d8b0eaf4cf73fa2d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9c37fbfca17c015bc22ef6ec3db7122
publicationDate	2013-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-101652142-B
titleOfInvention	Mineralocorticoid receptor antagonists
abstract	Compounds of the formula (I) are provided having a steroid skeleton and substitution characteristics in the A and B rings of the steroid skeleton effective for mineralocorticoid receptor antagonism, and rings C and D of the steroid skeleton having substituents thereon according to formula (I), wherein R1 is -OH or =O; R2 is (C1-3)alkyl or (C2- 3)alkenyl; R3 is selected from formulas (IIa), (IIb), (IIc). These compounds are useful in the treatment of inter alia aldosteronism, hypokalemia, hypertension, congestive heart failure, heart fibrosis, renal failure and restenosis.
priorityDate	2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9307878-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3094524-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4446072-A
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466237920

Total number of triples: 37.